McKesson Corporation (MCK) Revenue by Segment

McKesson revenue by segment at a glance

In Q1 fiscal 2027 (the quarter ended June 30, 2026), McKesson's largest business segment was North American Pharmaceutical, with $86.77 billion or 82% of revenue, up 4.9% from a year earlier. Next: Oncology and Multispecialty (13%), Medical-Surgical Solutions (3%) and Prescription Technology Solutions (1%).

By country, UNITED STATES brought in 85% and Non-US brought in 15% of revenue in Q1 fiscal 2021.

The fastest-growing business segment from a year earlier was Oncology and Multispecialty (+33.4%).

From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q2 fiscal 2018.

McKesson Corporation

MCKHealthcare

United States

Healthcare

Revenue breakdown

Fiscal quarters, from company filings

Segments by quarter (USD)

Click a bar to see that period below. Striped bars are calculated fourth quarters; an empty slot means it could not be calculated on the same basis i

U.S. PharmaceuticalU.S. Pharmaceutical and Specialty SolutionsNorth American PharmaceuticalInternationalMedical-Surgical SolutionsEuropean Pharmaceutical SolutionsOncology and MultispecialtyPrescription Technology SolutionsOther

Q1 FY27 breakdown

Fiscal quarter ended Jun 30, 2026

Item	Revenue	Share	vs year before
North American Pharmaceutical	USD 86.77B	82.3%	+4.9%
Oncology and Multispecialty	USD 14.22B	13.5%	+33.4%
Medical-Surgical Solutions	USD 2.82B	2.7%	+4.4%
Prescription Technology Solutions	USD 1.57B	1.5%	+9.2%

Sum of items USD 105.38B. Shares are of the items shown. Click an item with › to see its parts.

Also reported by:

All periods

Every item and period in one grid. Purple = calculated; "–" = not available.

Item	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24	Q1 FY24	Q4 FY23	Q3 FY23	Q2 FY23	Q1 FY23	Q4 FY22	Q3 FY22	Q2 FY22	Q1 FY22	Q4 FY21	Q3 FY21	Q2 FY21	Q1 FY21	Q4 FY20	Q3 FY20	Q2 FY20	Q1 FY20	Q4 FY19	Q3 FY19	Q2 FY19	Q1 FY19	Q4 FY18	Q3 FY18	Q2 FY18
U.S. Pharmaceutical	–	–	–	–	–	–	87.1B	85.7B	71.7B	68.8B	73.0B	69.8B	67.2B	–	61.9B	60.1B	56.9B	–	55.0B	53.4B	50.0B	47.0B	49.5B	48.1B	–	–	–	45.6B	–	–	–	–	–	–	–	–
U.S. Pharmaceutical and Specialty Solutions	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	45.1B	46.3B	46.9B	–	44.2B	40.9B	44.3B	41.6B	41.0B	–	42.0B	40.6B
North American Pharmaceutical	86.8B	79.1B	88.3B	86.5B	82.7B	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
International	–	–	–	–	–	–	3.9B	3.7B	3.7B	3.5B	3.6B	3.5B	3.5B	–	4.4B	6.2B	6.5B	–	9.5B	9.1B	9.2B	8.6B	9.3B	9.5B	–	–	–	9.3B	–	–	–	–	–	–	–	–
Medical-Surgical Solutions	2.8B	2.9B	3.0B	2.9B	2.7B	–	2.9B	2.9B	2.6B	2.8B	3.0B	2.8B	2.6B	–	3.0B	2.8B	2.6B	–	3.1B	3.1B	2.5B	2.7B	3.1B	2.5B	1.8B	2.2B	2.1B	2.1B	1.9B	2.0B	2.0B	1.9B	1.7B	–	1.7B	1.7B
European Pharmaceutical Solutions	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	6.2B	7.2B	6.9B	–	6.7B	6.8B	6.9B	6.6B	6.9B	–	7.0B	6.8B
Oncology and Multispecialty	14.2B	12.7B	13.0B	12.0B	10.7B	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Prescription Technology Solutions	1.6B	1.5B	1.5B	1.4B	1.4B	–	1.4B	1.3B	1.2B	1.2B	1.2B	1.1B	1.2B	–	1.1B	1.0B	1.1B	–	1.0B	932.0M	881.0M	789.0M	777.0M	668.0M	–	–	–	626.0M	–	–	–	–	–	–	–	–
All other segments	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2.6B	2.9B	3.2B	–	3.0B	2.8B	3.0B	–	–	–	–	–
Other Operating	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2.9B	3.0B	–	3.0B	3.0B
Reconciling items	–	101.0M	335.0M	302.0M	305.0M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

McKesson revenue by business segment, last 4 quarters

Business segment	Q1 FY27	Q3 FY26	Q2 FY26	Q1 FY26	Share
North American Pharmaceutical	$86.8B	$88.3B	$86.5B	$82.7B	82%
Oncology and Multispecialty	$14.2B	$13.0B	$12.0B	$10.7B	13%
Medical-Surgical Solutions	$2.8B	$3.0B	$2.9B	$2.7B	3%
Prescription Technology Solutions	$1.6B	$1.5B	$1.4B	$1.4B	1%

In USD, fiscal quarters as reported; share = part of Q1 FY27 revenue.

McKesson revenue by country, last 4 quarters

Country	Q1 FY21	Q3 FY20	Q2 FY20	Q1 FY20	Share
UNITED STATES	$47.1B	$49.3B	$48.3B	$46.3B	85%
Non-US	$8.6B	$9.9B	$9.3B	$9.4B	15%

In USD, fiscal quarters as reported; share = part of Q1 FY21 revenue.

Questions and answers

What are McKesson's business segments?

North American Pharmaceutical, Oncology and Multispecialty, Medical-Surgical Solutions and Prescription Technology Solutions (as reported for Q1 fiscal 2027).

Which business segment makes the most money for McKesson?

North American Pharmaceutical: $86.77 billion, or 82% of revenue, in Q1 fiscal 2027.

Where does McKesson make its money?

By country in Q1 fiscal 2021: UNITED STATES (85%) and Non-US (15%).

MoreMcKesson stock overview McKesson financials McKesson executive team McKesson shareholders

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.